Access

Letter

Nature 452, 365-369 (20 March 2008) | doi:10.1038/nature06641; Received 1 November 2007; Accepted 9 January 2008

Open Innovation Challenges

  • Methods to Analyze Consumer Emotions

    • Deadline: Jan 17 2010
    • Reward: $10,000 USD

    The Seeker is looking for methods to analyze consumer emotions. This Challenge requires only a writ...

  • Single-cell Analysis Platform

    • Deadline: Dec 02 2009
    • Reward: $5,000 USD

    This Challenge is looking for novel approaches to analyzing changes at a single-cell level. This is...

naturejobs

Control of chromosome stability by the bold beta-TrCP–REST–Mad2 axis

Daniele Guardavaccaro1, David Frescas1, N. Valerio Dorrello1, Angelo Peschiaroli1, Asha S. Multani3, Timothy Cardozo2, Anna Lasorella4, Antonio Iavarone4, Sandy Chang3, Eva Hernando1 & Michele Pagano1

  1. Department of Pathology, and,
  2. Department of Pharmacology, NYU Cancer Institute, New York University School of Medicine, 550 First Avenue, MSB 599, New York, New York 10016, USA
  3. Department of Cancer Genetics, The MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, USA
  4. Institute for Cancer Genetics, Columbia University New York, New York 10032, USA

Correspondence to: Michele Pagano1 Correspondence and requests for materials should be addressed to M.P. (Email: michele.pagano@nyumc.org).

Top

REST/NRSF (repressor-element-1-silencing transcription factor/neuron-restrictive silencing factor) negatively regulates the transcription of genes containing RE1 sites1, 2. REST is expressed in non-neuronal cells and stem/progenitor neuronal cells, in which it inhibits the expression of neuron-specific genes. Overexpression of REST is frequently found in human medulloblastomas and neuroblastomas3, 4, 5, 6, 7, in which it is thought to maintain the stem character of tumour cells. Neural stem cells forced to express REST and c-Myc fail to differentiate and give rise to tumours in the mouse cerebellum3. Expression of a splice variant of REST that lacks the carboxy terminus has been associated with neuronal tumours and small-cell lung carcinomas8, 9, 10, and a frameshift mutant (REST-FS), which is also truncated at the C terminus, has oncogenic properties11. Here we show, by using an unbiased screen, that REST is an interactor of the F-box protein beta-TrCP. REST is degraded by means of the ubiquitin ligase SCFbeta-TrCP during the G2 phase of the cell cycle to allow transcriptional derepression of Mad2, an essential component of the spindle assembly checkpoint. The expression in cultured cells of a stable REST mutant, which is unable to bind beta-TrCP, inhibited Mad2 expression and resulted in a phenotype analogous to that observed in Mad2+/- cells. In particular, we observed defects that were consistent with faulty activation of the spindle checkpoint, such as shortened mitosis, premature sister-chromatid separation, chromosome bridges and mis-segregation in anaphase, tetraploidy, and faster mitotic slippage in the presence of a spindle inhibitor. An indistinguishable phenotype was observed by expressing the oncogenic REST-FS mutant11, which does not bind beta-TrCP. Thus, SCFbeta-TrCP-dependent degradation of REST during G2 permits the optimal activation of the spindle checkpoint, and consequently it is required for the fidelity of mitosis. The high levels of REST or its truncated variants found in certain human tumours may contribute to cellular transformation by promoting genomic instability.

MORE ARTICLES LIKE THIS

These links to content published by NPG are automatically generated.